Update in the management of skeletal related events for metastatic prostate cancer: Denosumab, Alfaradin

ÇELİK S., Mungan U.

UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, vol.11, no.2, pp.164-167, 2012 (ESCI) identifier

  • Publication Type: Article / Review
  • Volume: 11 Issue: 2
  • Publication Date: 2012
  • Journal Name: UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY
  • Journal Indexes: Emerging Sources Citation Index (ESCI)
  • Page Numbers: pp.164-167
  • Keywords: prostate cancer, bone metastasis, alfaradin, denosumab
  • Dokuz Eylül University Affiliated: Yes

Abstract

Bone metastases are the most important cause of morbidity and mortality in men with prostate cancer. Skeleton related events (SRE) associated with bone metastases is a major health and economic problem in these patients. Zoledronic acid was the first treatment choice for prevention of bone loss and metastases in prostate cancer. However due to the difficulty in application of zolendronic acid and adverse effects of the drug on renal function, other treatment options were being investigated.